AstraZeneca's Q2 2026 financial report highlighted the oncology asset Truqap, an AKT inhibitor, as a standout performer. Initially undervalued upon launch (Evaluate Pharma projected a peak of $690 million), the drug has generated a steep and impressive sales curve in less than three years. Q2 2026 saw quarterly revenue of $233 million, with accelerating momentum, leading some overseas analysts to project a peak sales potential of $3 billion for Truqap. On the other side of the globe, another potential best-in-class AKT inhibitor is preparing for its market entry. On August 11th, LAEKNA-B (02105)'s LAE002 (Afuresertib), in partnership with Qilu Pharmaceutical, had its NDA accepted by the CDE, with an anticipated approval and commercial launch in 2027. Notably, Qilu Pharmaceutical secured the exclusive Greater China rights for LAE002 for an upfront payment and clinical development milestones totaling up to ¥5.3 billion, a sum that ranks among the highest in the history of domestic drug licensing deals for Greater China. The convergence of a "blockbuster overseas drug plus a major domestic pharmaceutical company's heavy investment" makes it hard not to be optimistic about LAE002's future market potential.

Truqap's consistent outperformance suggests LAE002 will follow suit

The commercial success of Truqap is built on a massive unmet clinical need in second-line and later HR+/HER2- metastatic breast cancer (mBC). HR+/HER2- is the largest subtype of breast cancer. The standard first-line treatment is endocrine therapy combined with a CDK4/6 inhibitor. The problem emerges after resistance develops: following CDK4/6i failure, median progression-free survival (mPFS) drops sharply from over two years to just a few months. This later-line market has long lacked a unified standard of care, relying on genetic testing to segment patients. Among these, patients with PAM pathway alterations (PIK3CA/AKT1/PTEN) account for roughly 50% of second-line patients and represent Truqap's target market. Within the PAM pathway mutation market, there were no approved targeted therapies for patients with AKT1 or PTEN mutations before Truqap. Within a year of its launch, Truqap's market share in these two subpopulations has approached 100%. The main competitive battle is for the larger PIK3CA mutation group, where Truqap's primary rival has been Novartis's PI3Kα inhibitor, Alpelisib. In reality, Alpelisib's market share is being steadily eroded by Truqap. Truqap's success in the PIK3CA segment is attributed to its balance of efficacy and safety, particularly tolerability. Alpelisib has a 63.7% incidence of any-grade hyperglycemia, with Grade 3 or higher at 36.6%, meaning nearly 40% of patients experience severe hyperglycemia requiring drug intervention, often leading to dose reduction or discontinuation. In contrast, Truqap's CAPItello-291 trial showed a Grade 3 or higher hyperglycemia rate of only 2.3%. The need for long-term metabolic monitoring for hyperglycemia makes clinicians more inclined to switch to Truqap. Truqap's overseas success in "capturing existing market share through superior tolerability" provides a valuable reference for understanding LAE002's potential. As a potential best-in-class molecule, LAE002 is well-positioned to replicate this logic across the dimensions of "efficacy, safety, and dosing convenience." Efficacy is paramount. The Phase III AFFIRM-205 trial, announced in April 2026, yielded strong, positive top-line results, successfully meeting its primary endpoint by demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the control group. Dosing convenience is a key commercial advantage. LAE002 is administered as a convenient 125 mg once-daily continuous regimen, whereas Truqap follows a complex intermittent schedule of 400 mg twice daily for four days on and three days off, making LAE002's regimen clearly more favorable for patient compliance. Regarding safety, the company reported that patients in the AFFIRM-205 trial tolerated the treatment well, with a very low discontinuation rate due to adverse events. In the CAPItello-291 trial, capivasertib had a 42% incidence of Grade 3 or higher treatment-emergent adverse events (TEAEs) and a discontinuation rate due to adverse events exceeding 10%. A lower incidence of Grade 3 adverse events is a key feature of LAE002 as a BIC candidate. It's important to note these are indirect cross-trial comparisons, not head-to-head data. However, the direction is clear: Truqap has proven this market segment is valuable and can generate rapid sales growth. With data that is comparable or superior in efficacy, dosing regimen, and tolerability, LAE002 has a clear foundation to replicate this success path, both in its domestic Chinese commercialization and potentially in global competition.

FDA approval for CAPItello-281 opens the door to a larger oncology market

If breast cancer established the AKT inhibitor's potential to cross the blockbuster threshold, then the FDA's June 2026 approval for prostate cancer solidified its ability to become a major drug. On June 12, 2026, the FDA approved Truqap in combination with abiraterone and prednisone for PTEN-deficient mAPMN/S (formerly mHSPC) prostate cancer. This was based on the Phase III CAPItello-281 trial, which showed a 19% reduction in the risk of radiographic progression-free survival (rPFS) (HR=0.81), extending median rPFS from 25.7 months to 33.2 months. This milestone marks the expansion of AKT inhibitors to a second major tumor type, validating that AKT pathway blockade can translate into clinical benefit beyond breast cancer. Importantly, the market size for prostate cancer is comparable to breast cancer. PTEN loss or AKT pathway activation occurs more frequently in prostate cancer than in breast cancer, affecting approximately one-quarter of mAPMN/S patients. Following Truqap's prostate cancer approval, foreign investment banks generally revised upward their expectations for it to surpass the $1 billion sales threshold. Turning to LAE002, it is pursuing a differentiated strategy in prostate cancer using its proprietary combination of "LAE002 + LAE001." The advantages can be analyzed from mechanistic, data, and market perspectives. Mechanistically, LAE001 is a dual CYP17A1/CYP11B2 inhibitor, recognized by Frost & Sullivan as a next-generation androgen synthesis inhibitor. LAE002 blocks the key resistance mechanism of the AKT pathway, and their combination creates a dual attack of "androgen synthesis inhibition + pathway blockade." This combination is proprietary to LAEKNA-B, offering greater control over patents and the pipeline. From a data perspective, the Phase II LAE201 study enrolled 40 patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after 1 to 3 lines of standard therapy (including abiraterone or second-generation AR antagonists). The median rPFS was 8.1 months, a significant improvement over the historical standard of care of 2 to 4 months. Based on this signal, the Phase III registration trial design was approved by the FDA in May 2024 as a global registrational study. In terms of market, AR pathway-targeted drugs for prostate cancer are in a large, expanding market. The AR inhibitor market in China alone is projected to grow from ¥7.2 billion in 2024 to ¥23.9 billion in 2030, a CAGR of 22% (according to brokerage estimates). Globally, there remains a significant unmet need for treating resistance in the castration-resistant stage (mCRPC), which is precisely the niche for LAE002 + LAE001. The clinical development strategies of Truqap and LAE002 differ notably. Truqap targets the hormone-sensitive phase (mHSPC/mAPMN/S), an earlier line of therapy. LAE002 is focused on the castration-resistant phase (mCRPC), following failure of ARPI therapies (e.g., abiraterone, enzalutamide), representing a later, more difficult-to-treat stage. However, their clinical development paths are similar: generating early signals, securing FDA approval for Phase III protocols, and then expanding from later lines to earlier lines of therapy. The success of CAPItello-281 does not guarantee LAE002's success in prostate cancer, but it is now established that AKT inhibitors can deliver value in this indication.

Future outlook: domestic and global market potential create a powerful synergy

Even within the domestic Chinese market, LAE002's potential is substantial. China bears one of the heaviest breast cancer burdens globally, with over 350,000 new cases and approximately 75,000 deaths in 2022. Furthermore, biomarker accessibility is improving. The proportion of PIK3CA/AKT1/PTEN alterations in the Chinese HR+/HER2- population is about 57%, higher than the global average of ~50%. In the CAPItello-291 China cohort, the risk reduction for disease progression or death was 59%, also higher than the 50% seen in the global population. A transparent peak sales estimate can be built from this patient funnel. Starting from 350,000 annual new cases, and accounting for the proportion of HR+/HER2- subtype, the rate of advanced/metastatic disease, the proportion of second-line and later treatment, and the biomarker positivity rate, the peak annual addressable patient pool is estimated at around 33,000 patients. Assuming an annual treatment cost of ¥150,000 (based on Capivasertib pricing), the fully addressable market would be approximately ¥5 billion. Modeling peak market shares of 25%, 50%, and 75%, LAE002's peak domestic sales from breast cancer alone could be ¥1.25 billion (conservative), ¥2.5 billion (base case), and ¥3.75 billion (optimistic), respectively. The potential for LAE002's overseas expansion is even more easily underestimated. The key is that the LAE002 + LAE001 combination is a global registrational study approved by the FDA. LAEKNA-B has only licensed out the Greater China rights for LAE002 to Qilu Pharmaceutical, retaining the rights for the rest of the world and already having a foundation for international multi-center clinical trials. The pricing for prostate cancer assets in the global BD market can be seen from some overseas examples. In February 2026, Astellas and Vir entered a global partnership for the prostate cancer asset VIR-5500, involving an upfront payment of $335 million ($240 million in cash plus $75 million in equity investment) and milestones up to $1.37 billion, for a total potential value of roughly $1.7 billion. Notably, VIR-5500 was still in Phase I at the time. Astellas's willingness to invest so early was directly driven by the impending patent expiry for its partnered drug, Xtandi, necessitating pipeline replenishment in prostate cancer. This demonstrates a strong willingness from major pharma to pay for prostate cancer assets, even without late-stage data. The LAE002 + LAE001 combination and the Astellas/Vir case share clear similarities: both target the large prostate cancer tumor type and both show early efficacy potential. The difference is that LAE002 has the backing of the AKT mechanism validated by the successful CAPItello-281 trial, a level of certainty that newer mechanism assets lack. Before Truqap's approval for prostate cancer, the market had barely priced in any expectation for LAE002's out-licensing overseas. The FDA's green light for CAPItello-281 has shifted this dynamic in a positive direction. In conclusion, by bringing these three threads together, we need to redefine LAE002's market potential. The proven overseas commercial model for the breast cancer indication, combined with Qilu Pharmaceutical's commercial commitment, has de-risked LAE002's domestic commercial future. The validation of the mechanism in prostate cancer and the readiness of the global Phase III trial provide a clear second growth curve. The gradually emerging expectation for overseas licensing represents a significant hidden option. $1 billion or $3 billion? Regardless, we are poised to witness the realization and growth of this future blockbuster.